subject: Acute Ischemic Stroke - Drug Pipeline Analysis and Market Forecasts to 2015 [print this page] Acute Ischemic Stroke - Drug Pipeline Analysis and Market Forecasts to 2015
Summary
The industry analysis specialist's new report, "Acute Ischemic Stroke Drug Pipeline Analysis and Market Forecasts to 2015" is an essential source of information and analysis on the global Acute Ischemic Stroke (AIS) market. The report identifies the key trends shaping and driving the global AIS market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global AIS sector.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData's team of industry experts.
Scope
The scope of the report includes:
- Annualized global AIS market revenues data from 2000 to 2008, forecast forward for 7 years to 2015.
- Geographies covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan.
- Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends. The pipeline candidates fall under the major categories like thrombolytics, neuroprotectants, anticoagulants, antiplatelets.
- Analysis of the current and future market competition in the global AIS market. Key future market players covered are Lundbeck, ThromboGenics and Vernalis holding the molecules that can directly treat the acute phase of the disease in the pipeline. Apart from these companies, Bayer, Bristol-Myers Squibb and Boehringer Ingelheim are found to be the companies with noticeable Phase III molecules for conditions like stroke prevention in atrial fibrillation.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with AIS.
Reasons to buy
The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
- Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global AIS market.
- Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global AIS market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What's the next big thing in the global AIS market landscape? Identify, understand and capitalize.
Companies Mentioned
Genentech, Boehringer Ingelheim, Kyowa Hakko, Mitsubishi Pharma, Lundbeck, PAION Deutschland GmbH, ThromboGenics, Vernalis plc., D-Pharm, Ferrer International S.A., Bayer, Johnson & Johnson Pharmaceutical Research and Development, L.L.C., Bristol-Myers Squibb, Pfizer
To know more about this report & to buy a copy please visit :
